Ely Benaim - Jul 30, 2021 Form 4 Insider Report for NovoCure Ltd (NVCR)

Role
Chief Medical Officer
Signature
/s/ Kimberly Burke Attorney in Fact for Ely Benaim
Stock symbol
NVCR
Transactions as of
Jul 30, 2021
Transactions value $
-$129,321
Form type
4
Date filed
8/3/2021, 05:29 PM
Previous filing
Jul 8, 2021
Next filing
Aug 4, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction NVCR Ordinary Shares Options Exercise $54.2K +651 +2.23% $83.30 29.8K Jul 30, 2021 Direct F1
transaction NVCR Ordinary Shares Sale -$103K -651 -2.18% $158.96* 29.1K Jul 30, 2021 Direct F1
transaction NVCR Ordinary Shares Sale -$80.1K -536 -1.84% $149.38 28.6K Aug 2, 2021 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction NVCR Options to Buy Ordinary Shares Options Exercise $0 -651 -16.68% $0.00 3.25K Jul 30, 2021 Ordinary Shares 651 $83.30 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Transaction was made pursuant to a Rule 10b-5-1 trading plan adopted by Dr. Benaim.
F2 Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted stock units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.
F3 Fully vested as of the date hereof.